Venetoclax for the treatment of multiple myeloma

Iuliana Vaxman, M. Hasib Sidiqi, Morie Gertz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory MM. Approximately, 20% of myeloma patients will exhibit t (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option. The efficacy of venetoclax is not uniquely restricted to this population. Areas covered: This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma. Expert commentary: Numerous phase 1/2 clinical trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting. These trials show better outcomes in the subgroup of patients harboring t(11;14).

Original languageEnglish (US)
Pages (from-to)915-920
Number of pages6
JournalExpert Review of Hematology
Volume11
Issue number12
DOIs
StatePublished - Dec 2 2018

Fingerprint

Multiple Myeloma
Therapeutics
Precision Medicine
Clinical Trials, Phase I
Hematologic Neoplasms
B-Cell Chronic Lymphocytic Leukemia
United States Food and Drug Administration
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
Safety
Recurrence
Pharmaceutical Preparations
Population

Keywords

  • BCL-2
  • Multiple myeloma
  • targeted therapy
  • venetoclax

ASJC Scopus subject areas

  • Hematology

Cite this

Venetoclax for the treatment of multiple myeloma. / Vaxman, Iuliana; Sidiqi, M. Hasib; Gertz, Morie.

In: Expert Review of Hematology, Vol. 11, No. 12, 02.12.2018, p. 915-920.

Research output: Contribution to journalArticle

Vaxman, Iuliana ; Sidiqi, M. Hasib ; Gertz, Morie. / Venetoclax for the treatment of multiple myeloma. In: Expert Review of Hematology. 2018 ; Vol. 11, No. 12. pp. 915-920.
@article{2daad49db9434f54974aba576dfae93d,
title = "Venetoclax for the treatment of multiple myeloma",
abstract = "Introduction: Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory MM. Approximately, 20{\%} of myeloma patients will exhibit t (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option. The efficacy of venetoclax is not uniquely restricted to this population. Areas covered: This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma. Expert commentary: Numerous phase 1/2 clinical trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting. These trials show better outcomes in the subgroup of patients harboring t(11;14).",
keywords = "BCL-2, Multiple myeloma, targeted therapy, venetoclax",
author = "Iuliana Vaxman and Sidiqi, {M. Hasib} and Morie Gertz",
year = "2018",
month = "12",
day = "2",
doi = "10.1080/17474086.2018.1548931",
language = "English (US)",
volume = "11",
pages = "915--920",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Venetoclax for the treatment of multiple myeloma

AU - Vaxman, Iuliana

AU - Sidiqi, M. Hasib

AU - Gertz, Morie

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Introduction: Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory MM. Approximately, 20% of myeloma patients will exhibit t (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option. The efficacy of venetoclax is not uniquely restricted to this population. Areas covered: This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma. Expert commentary: Numerous phase 1/2 clinical trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting. These trials show better outcomes in the subgroup of patients harboring t(11;14).

AB - Introduction: Treatment of multiple myeloma (MM) in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory MM. Approximately, 20% of myeloma patients will exhibit t (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option. The efficacy of venetoclax is not uniquely restricted to this population. Areas covered: This review will summarize the mechanism of action, toxicity profile, and published data on venetoclax use in MM, moving the field toward personalized medicine in the treatment of myeloma. Expert commentary: Numerous phase 1/2 clinical trials are evaluating the efficacy and safety of venetoclax monotherapy and in combinations in the relapse setting. These trials show better outcomes in the subgroup of patients harboring t(11;14).

KW - BCL-2

KW - Multiple myeloma

KW - targeted therapy

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85058190874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058190874&partnerID=8YFLogxK

U2 - 10.1080/17474086.2018.1548931

DO - 10.1080/17474086.2018.1548931

M3 - Article

C2 - 30428277

AN - SCOPUS:85058190874

VL - 11

SP - 915

EP - 920

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 12

ER -